Successfully Investing in Digital Health: a Guide for Pharma
It’s a strategic imperative for pharma to use its market position and money to shape and control the rapidly growing digital health space.Internal investment in digital health technology may be too little and acquisitions of established players could be too late and costly.
The operational benefits of digital health in terms of clinical trials, patient engagement, real world data and efficient workflow processes must be realised early. It’s time for pharma to step up to the plate. But when is a deal a good deal? Which funding model is optimal and in what circumstances? What are the attributes of an ideal startup investment partner?
For answers to these critical questions look no further than Pharma Investment in Digital Health: Strategies for success. The report reviews the latest 2016 deals and through expert insight identifies the critical strategic and tactical issues pharma must address if digital health investment is to bring both operational advantage and commercial ROI.